1
|
Blanc AL, Guignard B, Desnoyer A, Grosgurin O, Marti C, Samer C, Bonnabry P. Prevention of potentially inappropriate medication in internal medicine patients: A prospective study using the electronic application PIM-Check. J Clin Pharm Ther 2018; 43:860-866. [PMID: 29978537 DOI: 10.1111/jcpt.12733] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Accepted: 06/10/2018] [Indexed: 11/26/2022]
Abstract
WHAT IS KNOWN Potentially inappropriate medication (PIM) is a risk factor for drug-related problems (DRPs) and an important inpatient safety issue. PIM-Check is a screening tool designed to detect PIM in internal medicine patients. OBJECTIVE This study aimed to determine whether PIM-Check could help to identify and reduce DRPs. METHOD Prospective interventional study conducted on patients admitted to internal medicine wards in a university hospital between 1 September 2015 and 30 October 2015. Adult patients were included if they were hospitalized for more than 48 hours. Patients received either usual care (period 1 = control) or usual care plus medication screening by the wards' chief residents using PIM-Check (period 2 = intervention). An expert panel, composed of a clinical pharmacist, a clinical pharmacologist and two attending physicians in internal medicine, blinded to patient groups, identified DRPs. RESULTS A total of 297 patients were included (intervention: 109). The groups' demographic parameters were similar. The expert panel identified 909 DRPs (598: control; 311: intervention). The mean number of DRPs per patient was similar in the control (3.2; 95% CI: 2.9-3.5) and intervention groups (2.9; 95% CI: 2.4-3.3) (P = .12). PIM-Check displayed 33.4% of the 311 DRPs identified in the intervention group. WHAT IS NEW AND CONCLUSION In this study, PIM-Check had limited value, as the average number of DRPs per person was similar in both groups. Although one-third of DRPs counted in intervention group had been identified by PIM-Check, this did not lead to a reduction in DRPs. This lack of impact of PIM-Check on drug prescription may be explained by the number of alerts displayed by the application and hospital physicians' reluctance to modify the treatments for chronic conditions previously prescribed by general practitioners.
Collapse
Affiliation(s)
- A-L Blanc
- Pharmacy, Geneva University Hospitals, Geneva, Switzerland.,School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| | - B Guignard
- Pharmacy, Geneva University Hospitals, Geneva, Switzerland.,Clinical Pharmacology and Toxicology Department, Geneva University Hospitals, Geneva, Switzerland
| | - A Desnoyer
- Pharmacy, Geneva University Hospitals, Geneva, Switzerland.,Faculty of Pharmacy, University Paris-Saclay, Châtenay-Malabry, France
| | - O Grosgurin
- Internal Medicine and Rehabilitation Department, Geneva University Hospitals, Geneva, Switzerland
| | - C Marti
- Internal Medicine and Rehabilitation Department, Geneva University Hospitals, Geneva, Switzerland
| | - C Samer
- Clinical Pharmacology and Toxicology Department, Geneva University Hospitals, Geneva, Switzerland
| | - P Bonnabry
- Pharmacy, Geneva University Hospitals, Geneva, Switzerland.,School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| |
Collapse
|
2
|
Calmy A, van Delden C, Giostra E, Junet C, Rubbia Brandt L, Yerly S, Chave JP, Samer C, Elkrief L, Vionnet J, Berney T. HIV-Positive-to-HIV-Positive Liver Transplantation. Am J Transplant 2016; 16:2473-8. [PMID: 27109874 DOI: 10.1111/ajt.13824] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Revised: 04/08/2016] [Accepted: 04/09/2016] [Indexed: 01/25/2023]
Abstract
Most countries exclude human immunodeficiency virus (HIV)-positive patients from organ donation because of concerns regarding donor-derived HIV transmission. The Swiss Federal Act on Transplantation has allowed organ transplantation between HIV-positive donors and recipients since 2007. We report the successful liver transplantation from an HIV-positive donor to an HIV-positive recipient. Both donor and recipient had been treated for many years with antiretroviral therapy and harbored multidrug-resistant viruses. Five months after transplantation, HIV viremia remains undetectable. This observation supports the inclusion of appropriate HIV-positive donors for transplants specifically allocated to HIV-positive recipients.
Collapse
Affiliation(s)
- A Calmy
- HIV Unit, Geneva University Hospitals, Geneva, Switzerland
| | - C van Delden
- Transplant Infectious Diseases Unit, Geneva University Hospitals, Geneva, Switzerland
| | - E Giostra
- Division of Transplantation, Geneva University Hospitals, Geneva, Switzerland
| | - C Junet
- Private Practice, Geneva, Switzerland
| | - L Rubbia Brandt
- Division of Pathology, Geneva University Hospitals, Geneva, Switzerland
| | - S Yerly
- Virology Laboratory, Geneva University Hospitals, Geneva, Switzerland
| | - J-P Chave
- Private Practice, Lausanne, Switzerland
| | - C Samer
- Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland
| | - L Elkrief
- Division of Transplantation, Geneva University Hospitals, Geneva, Switzerland
| | - J Vionnet
- Division of Gastroenterology and Division of Transplantation, CHUV, Lausanne, Switzerland
| | - T Berney
- Division of Transplantation, Geneva University Hospitals, Geneva, Switzerland
| | | |
Collapse
|
3
|
Wagner N, Wyler-Lazarevic C, Yerly S, Samer C, Peytavin G, Posfay-Barbe K, Calmy A, Ambrosioni J. Corrigendum to “Dolutegravir-based antiretroviral therapy in a severely overweight child with a multi-drug resistant human immunodeficiency virus infection. A case report and review” [New Microbes New Infect] 6 (2015) 1–4]. New Microbes New Infect 2015; 8:174. [PMID: 27257500 PMCID: PMC4877397 DOI: 10.1016/j.nmni.2015.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
4
|
Storelli F, Bruggmann C, Doffey-Lazeyras F, Samer C, Desmeules J, Daali Y. Evaluation of CYP450 and transporters expression and activity in heparg cell line under different conditions. Clin Ther 2015. [DOI: 10.1016/j.clinthera.2015.05.281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Wagner N, Wyler-Lazarevic CA, Yerly S, Samer C, Peytavin G, Posfay-Barbe KM, Calmy A, Ambrosioni J. Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review. New Microbes New Infect 2015; 6:1-4. [PMID: 26082840 PMCID: PMC4430707 DOI: 10.1016/j.nmni.2015.02.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2014] [Revised: 02/02/2015] [Accepted: 02/18/2015] [Indexed: 12/03/2022] Open
Abstract
The management of multidrug-resistant human immunodeficiency virus (MDR HIV) infections in children is particularly challenging due to the lack of experience with new drugs. Dolutegravir, combined with an optimized antiretroviral background therapy, is promising for the treatment of MDR HIV and has been approved recently for adults and adolescents. Data for children are extremely limited. We describe the efficacy, safety and plasmatic levels of a dolutegravir-based, complex active antiretroviral treatment regimen in a severely overweight 11-year-old child infected with an MDR HIV strain.
Collapse
Affiliation(s)
- N Wagner
- Department of Paediatrics, Switzerland
| | | | - S Yerly
- Laboratory of Virology, Department of Genetics and Laboratory Medicine, Switzerland
| | - C Samer
- Division of Clinical Pharmacology and Toxicology, University Hospitals of Geneva, Switzerland
| | - G Peytavin
- Department of Clinical Pharmaco-Toxicology, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France
| | | | - A Calmy
- Division of Infectious Diseases, Department of Medical Specialties, Geneva University, Geneva, Switzerland
| | - J Ambrosioni
- Division of Infectious Diseases, Department of Medical Specialties, Geneva University, Geneva, Switzerland ; Infectious Diseases Department, Hospital-Clinic-IDIBAPS, Barcelona, Spain
| |
Collapse
|
6
|
Marsousi N, Daali Y, Humphries H, Almond L, Dayer P, Desmeules J, Samer C. PP189—A Physiologically-Based Mechanistic Pharmacokinetic Model to Assess the Metabolism of Oxycodone in Healthy Volunteers: Interplay Between CYP3A and 2D6 Inhibition. Clin Ther 2013. [DOI: 10.1016/j.clinthera.2013.07.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
7
|
Ing Lorenzini K, Samer C, Pugin J, Harbarth S, Bonnabry P, Fathi M, Dayer P, Desmeules J. PP197—Therapeutic Drug Monitoring of Vancomycin and Aminoglycosides in an Intensive Care Unit, a Retrospective Study. Clin Ther 2013. [DOI: 10.1016/j.clinthera.2013.07.227] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Guignard B, Samer C, Perrier A, Bonnabry P, Dayer P, Desmeules J. PP008—Drug-related problems in a general internal medicine service. Clin Ther 2013. [DOI: 10.1016/j.clinthera.2013.07.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Samer C, Doffey-Lazeyras F, Sorg O, Saurat JH, Dayer P, Daali Y, Desmeules J. PP233—CYP1A activity after chronic exposure to dioxins from a waste incinerator. Clin Ther 2013. [DOI: 10.1016/j.clinthera.2013.07.273] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Bosilkovska M, Deglon J, Samer C, Walder B, Dayer P, Desmeules J, Staub C, Daali Y. PP193—Simultaneous LC-MS/MS Quantification of P-Glycoprotein and Cytochrome P450 Probe Substrates and Their Metabolites In Dried Blood Spots. Clin Ther 2013. [DOI: 10.1016/j.clinthera.2013.07.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Baudet H, McLin V, Parvex P, Chehade H, Combescure C, Samer C, Bonnabry P, Fonzo-Christe C, Posfay-Barbe K. TDM and stabilisation of paediatric patients in liver and kidney transplantation. Eur J Hosp Pharm 2012. [DOI: 10.1136/ejhpharm-2012-000074.287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
12
|
Daali Y, Samer C, Déglon J, Thomas A, Chabert J, Rebsamen M, Staub C, Dayer P, Desmeules J. Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot. Clin Pharmacol Ther 2012; 91:489-96. [PMID: 22237256 DOI: 10.1038/clpt.2011.247] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We investigated whether a single blood measurement using the minimally invasive technique of a finger prick to draw a blood sample of 5 µl (to yield a dried blood spot (DBS)) is suitable for the assessment of flurbiprofen (FLB) metabolic ratio (MR). Ten healthy volunteers who had been genotyped for CYP2C9 were recruited as subjects. They received FLB alone in session 1 and FLB with fluconazole in session 2. In session 3, the subjects were pretreated for 4 days with rifampicin and received FLB with the last dose of rifampicin on day 5. Plasma and DBS samples were obtained between 0 and 8 h after FLB administration, and urine was collected during the 8 h after administration. The pharmacokinetic profiles of the drugs were comparable in DBS and plasma. FLB's apparent clearance values decreased by 35% in plasma and DBS during session 2 and increased by 75% in plasma and by 30% in DBS during session 3. Good correlations were observed between MRs calculated from urine, plasma, and DBS samples.
Collapse
Affiliation(s)
- Y Daali
- Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Ancrenaz V, Daali Y, Fontana P, Besson M, Samer C, Dayer P, Desmeules J. Impact of Genetic Polymorphisms and Drug – Drug Interactions on Clopidogrel and Prasugrel Response Variability. Curr Drug Metab 2010; 11:667-77. [DOI: 10.2174/138920010794233521] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2010] [Accepted: 09/30/2010] [Indexed: 11/22/2022]
|